Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Collagen Solutions raising up to £12mln to fund commercial transformation

"the capital will provide the company with the opportunity to fund the development of a range of exciting new products for use in the rapidly emerging field of regenerative medicine,” said chief executive Jamal Rushdy.
Collagen Solutions raising up to £12mln to fund commercial transformation
The new products will be used in regenerative medicine

Collagen Solutions PLC (LON:COS) is planning to raise up to £12mln issuing equity and debt, which will help accelerate the growth of the business.

It is raising the bulk of the new monies from investors via a placing and open offer that could bring in as much as £8mln. At 5p each, the shares are being sold at 17% discount Monday’s closing price.

A further £4mln will provided by finance house Norgine Ventures, which will subscribe to bonds with warrants attached.

Chief executive Jamal Rushdy called the funding round “strategically important”.

WATCH: CEO Jamal Rushdy talks Proactive's Andrew Scott through 'transformational' fundraise

Not only does it strengthen the balance sheet, it “provides the resources to accelerate our core biomaterials and tissue business”, he said.

“Furthermore, the capital will provide the company with the opportunity to fund the development of a range of exciting new products for use in the rapidly emerging field of regenerative medicine,” Rushdy added.

It is looking to develop and launch new, higher value “finished device products”, which will supplement the revenues from base business – the supply of bovine collagen materials.

As the company points out in its statement, while the revenue stream from the current operation is stable and long-term, the sales cycle is often “long and complex”.

So, Collagen Solutions is moving up the value chain with products such ChondroMimetic, an implant used to treat cartilage and underlying bone defects.

It also plans to go ahead with bone graft and wound treatment collagen devices.

“The company's expertise, experience, and infrastructure in collagen and tissue engineering can be leveraged to move up the value chain to produce its own finished devices, which can address current customer needs to improve their own product portfolios with immediately available and differentiated products,” Collagen’s release earlier Tuesday said.

“The company expects to invest in developing those higher value finished device products as part of a longer term collaborative relationship with its customers.”

--- Updates for CEO Video ---


View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use